Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib vs TKIs in advanced hepatocellular carcinoma after immune checkpoint inhibitor failure
CTR20211710Phase 3Terminated
- Sponsor
- Suzhou Sundia Biotech Co., Ltd.
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Suzhou Sundia Biotech Co., Ltd. Primary endpoints: Objective response rate - phase 1 portion and Overall survival - phase 2 portion. Started Jul 2021; status: terminated.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20211710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211710.